openPR Logo
Press release

HPAPI 2019 Conference: Exclusive Interview Released with AstraZeneca

03-21-2019 12:53 PM CET | Media & Telecommunications

Press release from: SMi Group

HPAPI 2019 Conference: Exclusive Interview Released with

Peter Marshall from AstraZeneca will be speaking at SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference which will take place in London on 13th-14th May. He will be discussing the latest developments in the industry with a specific focus on the principles of pharmaceutical containment in isolator design. Ahead of the conference, SMi had interviewed him where he gave a taster of what he will be discussing.

Peter said:

“The HPAPI market is becoming more entrenched across the Pharma industry. Historically major pharma and some specialist contract manufacturers have led the field in design and application, but the more general toxic nature of new products has required many more companies to consider investment in contained facilities. Further to this, new drug modalities such as ADCs (antibody-drug conjugates) have presented enhanced containment challenges due to the elevated toxicity of some of the components. Finally, the toxicity of some modern inhaler and other device products has raised the importance of containment in device-related process approaches including dry powder and aseptic filling processes.”

“For me personally, the problem is often being involved in the early stages of a project to ensure that exposure control is properly considered, and optimal strategies and technologies are applied. In my opinion there are too many simplistic design or equipment selection tools which are used blindly without an understanding of their relevance and validity. In some cases these can lead to excessively conservative technology decisions which present significant operability and maintenance issues for the final user.”

The full interview is available in the Download Centre on the website.

Key sessions to be discussed in the area of containment include – Antibody-drug conjugate manufacturing, adaptation of containment designs to cope with the high demands of HPAPIs and the challenges verifying containment performance of a HPAPI OSD facility.

Joining Peter on Day Two of the conference will be Dr Thomas Nittoli, Director, Regeneron; Dr Jeff Parry, Senior Formulation Scientist, AstraZeneca and Mr Nigel Saunders, Technical Engineer – SME Containment, GSK.

Sponsors include: BSP Pharmaceuticals | Minakem | PCi Pharma Services | SafeBridge Consultants Inc. | Solo Containment

SMi offer unique sponsorship, exhibition and branding packages, tailored to complement your company’s marketing strategy. Contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 / Email: nhoward@smi-online.co.uk

Conference Organisers

India House, 45 Curlew Street, London, SE1 2ND

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HPAPI 2019 Conference: Exclusive Interview Released with AstraZeneca here

News-ID: 1665853 • Views: 672

More Releases from SMi Group

Registration is now open for SMi’s Inaugural Medical Wearables for Biosensors …
SMi Reports: Registration is open for the Inaugural Medical Wearables for Biosensors Conference taking place October 25th – 26th in Boston, USA. As part of SMi’s leading series of medical device conferences, this year’s event will bring together expertise from individuals in multiple disciplines in the field of body-worn sensors and connected devices. The two-day conference will offer a series of presentations, through which you will gain insight into on-body devices for
Registration is now open for Pre-filled Syringes San Francisco Conference 2021
SMi Reports: Registration has opened for the 2nd annual Pre-Filled Syringes San Francisco taking place on 13th – 14th September. As part of SMi’s leading Injectables series, this year’s event will address the key drivers of the pre-filled syringes and combination products industry to give a comprehensive insight into the latest device innovations, regulatory updates and future insights for the coming year. Visit the event website to learn more and download
How a hard Brexit will impact the EU market and the effects of Parallel Trade pr …
SMi Reports: Exploring the challenges, practices and drivers in the aftermath of the transition for Parallel Trade. Join us at SMi’s 15th annual Parallel Trade Conference bringing together industry experts from leading experts to discuss the challenges and drivers of the industry, including the EU regulatory landscape and the impact of the FMD. Collaborate and share ideas of how a hard Brexit will impact the EU market and the effects of Parallel
Registration closing soon for SMi Group’s 14th Annual Border Security Conferen …
SMi Group reports: The Border Security conference hosted by SMi Group is taking place virtually in less than two weeks’ time. SMi Group's 14th annual Border Security conference will be closing in less than two weeks' time. For those interested in attending, important information about the event as well as the preliminary attendee list is released below. Registration is FREE for military and government personnel, and just £499 for commercial

All 5 Releases


More Releases for HPAPI

High Potency Active Pharmaceutical Ingredients (HPAPI) Market Outlook To 2024
High Potency Active Pharmaceutical Ingredients (HPAPI) Market Outlook To 2024: Key Product Categories (Synthetic, Biotech), Type (Innovative, Generic), End-Use (Oncology, Hormonal, Glaucoma), Regional Segmentation, Competitive Dynamics, Pricing Analysis (OPP, IPP, RAP) And Segment Forecast The global high potency active pharmaceutical Ingredients (HPAPI) Market was valued at $14.36 billion in 2016 and is forecast to grow at a steady CAGR of 8.4% between 2017 and 2024, culminating in 2024 global revenue of
Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Researc …
This report studies the global High Performance Active Pharmaceutical Ingredients (HPAPI) market status and forecast, categorizes the global High Performance Active Pharmaceutical Ingredients (HPAPI) market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Bristol-Myers Squibb Novartis Sanofi Aventis Pfizer Lonza Novasep Hospira
The Latest Techniques in HPAPI Facility Design
Amongst the myriad of potential pitfalls for the Highly Potential Active Pharmaceutical Ingredients (HPAPI) industry there is a requirement for all parties involved to have a blueprint in place to ensure all containment procedures are followed correctly. Yet, there is also a need to ensure that operations are maintained at the highest standards. At SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients Conference these issues will be discussed along with
HPAPI (High Potency Active Pharmaceutical Ingredients) Market Report 2018: Segme …
Global HPAPI (High Potency Active Pharmaceutical Ingredients) market research report provides company profile for Lonza, Novasep, Thermofisher Scientific, Alkermes, Cambrex, Dishman, Dr. Reddy’S and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report
SMi’s HPAPI 2018 Conference: Exclusive Interview Released with HPAPI Project S …
SMi are delighted to have our Chairman, Speaker and Workshop Host, Justin Mason-Home, Director, HPAPI Project Services Limited, onto the speaker panel for HPAPI 2018! About Justin: Justin Mason-Home is an organic chemist with extensive health, safety, environmental and chemical engineering experience in senior technical, legal and commercial aspects of the pharmaceutical, biochemical, chemical and other industries. He has held senior positions and worked globally in potent biopharmaceutical occupational health and safety
Exclusive Interview Released with HPAPI Project Services
SMi are delighted to have our Chairman, Speaker and Workshop Host, Justin Mason-Home, Director, HPAPI Project Services Limited, onto the speaker panel for HPAPI 2018! About Justin: Justin Mason-Home is an organic chemist with extensive health, safety, environmental and chemical engineering experience in senior technical, legal and commercial aspects of the pharmaceutical, biochemical, chemical and other industries. He has held senior positions and worked globally in potent biopharmaceutical occupational health and safety